Saturday 17 October 2026
Export ANEB’s income statement to Excel — free account
Anebulo Pharmaceuticals, Inc.
ANEB Healthcare Biotechnology
In the quarter to December 2025, EPS grew 44.4% and free cash flow grew 6.58%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.00
0.31
−100.00%
Follow ANEB
Anebulo Pharmaceuticals, Inc. (ANEB) P/E ratio
Anebulo Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DYAI Dyadic International Inc. compare | n/m |
| NEUP Neuphoria Therapeutics Inc. compare | n/m |
| JSPR Jasper Therapeutics, Inc. compare | n/m |
| TCRX TScan Therapeutics, Inc. compare | n/m |
| ACGN Aceragen, Inc. compare | n/m |
| ANEB Anebulo Pharmaceuticals, Inc. | n/m |
| ATYR aTyr Pharma, Inc. compare | n/m |
| PBM Psyence Biomedical Ltd. compare | 0.2× |
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)